VIMTALABS Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹100.5 Cr
verification pending
Revenue YoY
10.2%
reported change
EBITDA
₹34.4 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Vimta Labs reported Q3 FY26 revenue of ₹100.5 crore (10.2% YoY), with EBITDA at ₹34.4 crore (34.3% margin, -184bps YoY) and PAT at ₹17.6 crore. The miss versus expectations stemmed from unexpected operational challenges during facility restructuring for analytical services expansion and lagged clinical trial bookings. Management flagged that Q4 should see recovery given seasonal tailwinds in food testing and normalized operations. The biologics CRDMO foray remains on track for Q1 FY27 commercialization, with equipment procurement complete and facility setup progressing. The ₹500 crore revenue target for FY26 may not be met, with management acknowledging they likely won't reach the quarterly run rate of ₹125 crore. Export revenues improved to ~39% of total income, with ~60% of exports from the US. Capex continues at depreciation levels plus additional investments for biologics capacity, temporarily pressuring ROC. Margins are guided to remain within ±1-2% of current levels as efficiency improvements offset rising manpower and input costs.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained the multi-year ₹500 crore revenue target for FY26 but acknowledged they may not reach the ₹125 crore quarterly run rate needed to achieve it, suggesting they will land below target.
- Management expects Q4 to be much better sequentially due to seasonal tailwinds in food testing and resolution of operational challenges from facility restructuring.
- Equipment procurement and facility setup for biologics contract research and development services is on track; management expects to commercialize by Q1 of next fiscal, though maiden year revenues will be modest.
- Management expects margins to remain within plus or minus 1-2% in the near term as digital transformation and workflow efficiencies offset rising manpower and input costs.
Risks flagged
- Facility modifications to accommodate analytical services expansion caused unexpected delays and impacted team productivity, resulting in revenue deferrals to Q4. Management declined to quantify the deferred revenue amount, making it difficult to assess the true recovery magnitude in Q4.
- Management explicitly stated the maiden year for biologics should not be judged by revenue targets, as the focus is on acquiring initial clients and building reputation. Full revenue contribution will take time, creating near-term margin dilution from setup costs.
- Attrition rates are high across the industry, and costs for manpower, chemicals, reagents, and standards continue to escalate. While management claims to offset these with efficiency gains, the cost inflation trajectory exceeds normal levels and poses ongoing margin risk.
- CFO explicitly acknowledged that ROC has dipped below 20% due to biologics capex with revenues yet to materialize. This creates a window of 1-2 quarters where capital efficiency metrics will remain depressed until the new vertical generates meaningful contribution.
Key quotes
- Are we going to come to the run rate of 125 crores which is basically what I have been trying to share? Maybe not. We may not touch that number but I feel we'll not be disappointed with where we land at by the end of the year.
- These EBITDA margins, I always say plus minus one or 2% they will be maintained at least in the near term.
- The environment is very conducive for companies to do well in this sort of a growing market. As such, we don't give any forward-looking statements with respect to numbers. I can just share my confidence on what we think would be good growth future for the company.
Research modules